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INTRODUCTION
Most patients who undergo a Kasai portoenterostomy for bili-
ary atresia (BA) develop chronic liver disease.1 Cholangitis, por-
tal hypertension, variceal bleeding, liver cirrhosis, ascites, or 
splenomegaly commonly occur after a Kasai portoenterostomy 
for BA.1-3 Hepatocellular carcinoma (HCC) that complicates 
biliary cirrhosis has also been reported in patients with BA.4,5
In a recent report, increased expression of cyclooxygenase-2 
(COX-2) in biliary epithelial cells was found in BA patients with 
severe liver dysfunction at the time of the Kasai procedure.6 
Overexpression of COX-2 has been demonstrated in inflamma-
tory, cirrhotic, or cancerous liver tissue,7-9 and many studies 
have tried to elucidate the role of COX-2 inhibitors (COX-2i) in 
hepatitis, portal hypertension, liver cirrhosis, and hepatic carci-
nogenesis using animal models.10-17 Among these studies, we 
previously reported the effect of a selective COX-2i in reduc-
ing hepatic fibrosis in rats with ligated common bile ducts.14
The purpose of our current study was to evaluate the effect of 
a COX-2i in ameliorating hepatic fibrosis or chronic inflamma-
tion in children with chronic liver disease.
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MATERIALS AND METHODS
Patient selection
The study protocol was explained to all patients (and their par-
ents) who were older than 2 years of age and who reported to 
our outpatient clinic for management of their BA after Kasai 
procedures. Patients, enrolled in the study and control groups, 
provided written informed consent, and they volunteered for 
the study or control group. Because the safety of the drug 
(meloxicam) used in the study group was not approved in chil-
dren younger than 2 years of age, patients younger than 2 years 
were excluded from both groups.
This clinical trial was registered at www.clinicaltrials.gov (trial 
identification number: NCT02298218).
Study group
From September 2009 to September 2010, patient volunteers 
who were over 2 years old, who had undergone a Kasai porto-
enterostomy for BA, and who were postoperatively managed in 
our outpatient clinic were prospectively enrolled in this study. 
The study was approved by the Ethics Committee of Severance 
Hospital (approval number 4-2008-0597). Serum and urine 
analysis, abdominal ultrasonography, and a stool occult blood 
test were performed as screening tests to determine hepatic 
and renal function and to exclude patients with hematologic 
diseases, varices, or ulcers. Endoscopy of the upper gastrointes-
tinal tract was not routinely performed as a screening test be-
cause of the invasiveness of endoscopy. If the stool occult blood 
test was positive, an endoscopy was performed to check for 
esophageal or gastric varices or ulcers. Patients with any hepat-
ic, renal, or hematologic abnormalities or abnormal endoscopic 
findings were excluded. For each patient, hepatic abnormali-
ties identified in the screening test were considered to be mark-
edly outstanding results from the range of their previous data of 
serum analysis or sonographic findings.
Although patients were originally grouped into high-dose or 
low-dose groups using a randomized sampling method, no im-
portant differences were found. Therefore, the data were com-
bined for all analyses. A selective COX-2i, meloxicam (Melax, 
Chong Kun Dang Pharm., Seoul, Korea) was prescribed to the 
patients once daily according to their grouping: 0.0625 mg/kg 
body weight in the low-dose group and 0.125 mg/kg in the 
high-dose group.
The degree of hepatic fibrosis was determined by the liver 
stiffness score (LSS) using a FibroScan (Echosens, Paris, France). 
The LSS was determined three times: baseline, 6 months, and 1 
year after enrollment in the study group. At the 6-month time 
point, if the score was elevated more than 10% compared to the 
baseline value, the patient was excluded from the study group. 
If the change in the LSS at 6 months was less than or equal to 
110%, the study drug was maintained for another 6 months. The 
LSS was determined at the 1-year time point, which correspond-
ed to the time of study completion. Liver function was checked 
by serum analysis before and after receiving the COX-2i.
Patients visited the outpatient clinic every 3 months to check 
for any adverse effects of the drug. Furthermore, serum analy-
sis, including a blood cell count, analysis of hepatic and renal 
function, urinalysis, abdominal ultrasonography, and a stool 
occult blood test were performed every 3 months. The trough 
level of the drug in the serum was checked to maintain the con-
centration of the drug in the proper range. If any suspicious ad-
verse effect of the drug was noted, the patient was excluded 
from the study.
Control group
The LSS has been determined in patients with BA every year at 
our outpatient clinic since the introduction of the FibroScan in 
2007. The control group included patients who were followed at 
our outpatient clinic after successful Kasai portoenterostomy 
for BA and who simultaneously had their LSS and serum total 
bilirubin measured two or more times during the post-opera-
tive follow-up period. LSS was measured two times every 6 
months after enrollment in the control group. We excluded the 
LSS from our analysis of patients in the control group when the 
LSS was measured with a success rate lower than 60%, when 
patients had hyperbilirubinemia (elevation of serum total bili-
rubin ≥1.0 mg/dL compared to the baseline), after a repeat-Ka-
sai procedure, or after liver transplantation. Except for medica-
tion with the COX-2i in the study group, all management 
procedures after the Kasai portoenterostomy were the same in 
both groups, including administration of ursodeoxycholic acid, 
antibiotics to prevent cholangitis, and the use of transient ste-
roid therapy.
Measurement of LSS
LSS was measured in both groups as described previously.18 In 
brief, the patient was placed in a supine position with maximal 
abduction of the right arm. Ten successful measurements of LSS 
were obtained with an ultrasound transduced probe on the 
right lobe of the liver through the intercostal spaces. The medi-
an value of the 10 measurements of LSS was calculated auto-
matically by software in FibroScan and expressed as LSS in kilo-
pascals (kPa).
Data analysis
The LSS and serum total bilirubin values in both groups were 
collected retrospectively for a period of 2 years before enroll-
ment in the study, and they were compared with those values 
after study enrollment. The median LSS value and the average 
of the serum total bilirubin for each patient were used as the 
baseline values.
Statistical analyses were performed using SPSS version 18.0 
software (SPSS Inc., Chicago, IL, USA) and SAS version 9.2 soft-
ware (SAS Institute Inc., Cary, NC, USA). Categorical parame-
ters were analyzed with Pearson’s chi-squared test. Continuous 
parametric data were analyzed with independent t test. Paired 
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non-parametric data were analyzed with Wilcoxon signed-rank 
test. The effects of the study drug on LSS, serum bilirubin, and 
liver enzymes were compared between the two groups using a 
linear mixed model. P values for multiple comparisons were 
adjusted with post-hoc analysis using Bonferroni’s correction. 
A p value less than 0.05 was considered statistically significant.
RESULTS
The clinical characteristics of both groups are presented in Ta-
ble 1. Twenty-five patients were enrolled in the study group (18 
females and 7 males) with an average age at enrollment of 
6.1±3.0 years. The control group included 44 patients (26 females 
and 18 males) with an average age at enrollment of 5.5±3.2 
years. The mean age at the time of Kasai portoenterostomy for 
BA was not significantly different between the two groups 
(66.3±36.6 days in the study group vs. 58.0±25.3 days in the con-
trol group; p=0.279). Thirteen patients (10 females and 3 males) 
were assigned randomly to the low-dose group prescribed 
0.0625 mg/kg body weight COX-2i, and 12 patients (8 females 
and 4 males) were assigned to the high-dose group prescribed 
0.125 mg/kg COX-2i.
The average value for serum total bilirubin before study en-
rollment was not different between the two groups (1.4±0.7 
mg/dL in the study group vs. 0.9±1.5 mg/dL in the control 
group; p=0.175). However, the mean LSS before study enroll-
ment was higher in the study group than in the control group 
(20.5±9.7 kPa in the study group vs. 11.8±8.9 kPa in the control 
group; p<0.001) (Table 1). The success rate of obtaining LSS be-
fore study enrollment was more than 90% in both groups 
(96.7±9.0% in the study group vs. 93.2±10.7% in the control 
group; p=0.153). During the study, no LSS data were excluded 
because all measured success rates of LSS were higher than 
80% in both groups.
The least square means (LSM) of the LSS in the study group 
were significantly decreased by 3.91±0.98 kPa at the 1-year time 
point. In contrast, the LSS in the control group did not change 
significantly during the study period with a difference of -0.29± 
0.70 kPa (p=0.004) (Fig. 1A). Serum total bilirubin levels did not 
change significantly in either group during the study period 
(Fig. 1B). Differences of the LSM of serum total bilirubin during 
the 1-year study period were -0.34±0.17 mg/dL in the study 
group and 0.02±0.08 mg/dL in the control group (p=0.071) (Table 
2). The liver enzymes [aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT)] in either group did not change 
significantly during the study period (Table 2, Fig. 1C and D).
During the study period, the mean serum drug level in the 
study group was 0.27±0.17 μg/mL. Considering the possible 
side effects of COX-2i, we performed serum analysis including 
a blood cell count, hepatic and renal function tests, urinalysis, 
abdominal ultrasonography, and stool occult blood test every 3 
months. LSS was measured 6 months after the start of medica-
tion. If the LSS was elevated by more than 10% at the 6-month 
time point compared to baseline, or if an abnormal finding 
showed up in the follow-up tests every 3 months, we excluded 
the patient from the study group to prevent the possible occur-
rence of hepatic toxicity or other adverse effect of the drug. 
Three patients in the study group (two in the high-dose group 
and one in the low-dose group) were excluded at the 6-month 
time point, because their LSS were elevated by more than 10% 
compared to baseline. However, the median values of their 
LSSs were not significantly different with 12.60 (7.75–27.90) kPa 
at baseline LSS and 13.50 (9.50–45.00) kPa at the 6-month time 
point (p=0.109). Moreover, serum total bilirubin and liver en-
zymes were unchanged at the 6-month time point (p=0.102 for 
serum total bilirubin, p=0.102 for AST, and p=0.109 for ALT).
Their elevated LSSs and the other data obtained at the 6-month 
time point were included in the data analysis as the study group 
without the data at the 12-month time point. Moreover, no ad-
verse effects due to COX-2i were noted in this study. The results 
of the serum analysis and the urinalysis indicated that hemato-
logic, hepatic, and renal function values were not affected by 
the use of COX-2i during the study. The occult blood test result 
was negative for every stool test. When they were asked during 
follow-up visits, none of the patients complained of nausea, 
vomiting, diarrhea, bloody stool, indigestion, abdominal pain, 
heartburn, chest discomfort or tightness, mood change, anxi-
Table 1. Clinical Characteristics of the Study Population
Study group (n=25) Control group (n=44) p value
Sex, n (%) 0.284
Male 7 (28.0) 18 (40.9)
Female 18 (72.0) 26 (59.1)
Mean age at study enrollment, yrs 6.1±3.0 5.5±3.2 0.479
Mean age at Kasai portoenterostomy for BA, days 66.3±36.6 58.0±25.3 0.279
Mean LSS (kPa) before study enrollment 20.5±9.7 11.8±8.9 <0.001
Mean TB (mg/dL) before study enrollment 1.4±0.7 0.9±1.5 0.175
Mean AST (IU/L) before study enrollment 82.6±47.2 57.6±44.3 0.063
Mean ALT (IU/L) before study enrollment 67.0±46.4 54.3±53.7 0.380
BA, biliary atresia; LSS, liver stiffness score; kPa, kilopascals; TB, serum total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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ety, change in appetite, skin rash, irritability, abnormal sensa-
tion, changes in vision, confusion, or loss of consciousness.
DISCUSSION
Despite the overall success of the Kasai procedure for BA,19,20 
many children with BA experience liver damage after the pro-
cedure.2 This liver damage, which includes fibrosis and cholan-
gitis, can lead to chronic liver disease with portal hypertension, 
cirrhosis, or even HCC and the need for a liver transplant.2-5,21,22 
Although approximately 80–90% of patients who undergo the 
Kasai procedure or even liver transplantation survive to adoles-
cence and beyond,2,3,20 these patients experience substantial 
Fig. 1. Changes in liver parameters according to the study time points for the study and control groups. (A) Median values of the liver stiffness score (LSS). 
(B) Mean values of serum total bilirubin (TB). (C) Mean values of aspartate aminotransferase (AST). (D) Mean values of alanine aminotransferase (ALT). 
The significant difference (p<0.05) is indicated with an asterisk. 
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Table 2. The Differences of Least Square Mean Values of the LSS, TB, and Liver Enzyme Values at Baseline, 6-Month, and 1-Year Time Points
Study group (n=25) Control group (n=44) p value
LSS (kPa)
6-month time point -2.36±1.22 -0.39±0.92 0.203
1-yr time point -3.91±0.98 -0.29±0.70 0.004
TB (mg/dL)
6-month time point -0.18±0.15 -0.13±0.06 0.756
1-yr time point -0.34±0.17 0.02±0.08 0.071
AST (IU/L)
6-month time point -0.42±8.86 -15.44±6.70 0.181
1-yr time point -13.41±8.40 -21.37±6.24 0.450
ALT (IU/L)
6-month time point -2.33±11.38 -15.42±8.58 0.362
1-yr time point -10.10±10.18 -22.75±7.46 0.320
LSS, liver stiffness scores; TB, serum total bilirubin; kPa, kilopascals; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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morbidity. Liver fibrosis and cirrhosis begin early in infants 
with BA.2 Corticosteroids may help limit inflammatory damage 
and increase bile flow, but their efficacy remains unclear.2,3 
Therefore, additional pharmacological treatments are required 
to improve liver function in these patients.
Overexpression of COX-2 in the liver has been observed in 
patients with chronic hepatitis, cirrhosis, and HCC,7-9,15,16 and 
COX-2 may mediate or worsen these conditions.6,7,9,15 Liver fi-
brosis is caused by cholestasis and collagen accumulation, and 
COX-2 is upregulated with these conditions.13 COX-2 expres-
sion also correlates with the stage of fibrosis.9 Mohammed, et 
al.7 analyzed COX-2 expression in cirrhotic livers after hepatitis 
B and C infection and found that COX-2 was absent in normal 
livers but high in cirrhotic livers. Jeong, et al.23 examined COX-2 
protein expression in 43 patients with chronic hepatitis and 24 
patients with cirrhosis using immunohistochemistry and found 
that COX-2 expression was higher in patients with cirrhosis and 
advanced fibrosis. Honsawek, et al.6 reported that COX-2 ex-
pression was increased in biliary epithelial cells at the time of 
Kasai portoenterostomy in patients with BA and was associated 
with an adverse postoperative outcome.
In addition, COX-2 may be involved in the development of 
HCC resulting from chronic liver disease. In patients with HCC 
and hepatitis C virus-related cirrhosis, overexpression of COX-2 
may accelerate the development of HCC, and higher COX-2 ex-
pression is a significant risk factor for recurrence of HCC in the 
residual liver.8 He, et al.24 evaluated COX-2 expression in the liv-
er of patients with HCC and showed that the recurrence-free 
survival rates in the COX-2-positive group were significantly 
lower than those in the COX-2-negative group. These authors 
speculated that overexpression of COX-2 in the noncancerous 
liver may predict cancer recurrence in patients with hepatitis B 
virus-related cirrhosis.24 Thus, blocking COX-2 activity may im-
prove liver function and prevent further damage in different 
groups of patients, including those with BA.
The effect of inhibiting COX-2 has been explored in several 
animal models of liver disease. In rats treated with carbon tetra-
chloride to induce liver cirrhosis, the COX-2i rofecoxib reduces 
portal pressure, collagen accumulation, and fibrogenesis.11 Us-
ing a similar rat model, Chávez, et al.12 showed that the COX-2i 
celecoxib prevents and reduces cholestatic damage and colla-
gen deposition, demonstrating the antifibrogenic and fibrolytic 
effects of this COX-2i. Similarly, carbon tetrachloride-treated 
mice given the COX-2i SC-236 show reduced liver fibrosis.13 In 
an animal study,14 we performed bile duct ligation in rats to in-
duce cholestasis, which triggers fibrogenesis in the liver, and 
subsequently treated the rats with the COX-2i meloxicam, and 
found that meloxicam reduces fibrosis and collagen accumula-
tion, with corresponding histological improvement of the liver 
by attenuating the expression of α-smooth muscle actin, trans-
forming growth factor-β1, COX-2, and matrix metalloprotein-
ase-9. The preventive effect of meloxicam was also reported in 
the rat hepatic ischemia/reperfusion injury model.15 Yamamo-
to, et al.10 showed that the COX-2i JTE-522 prevents liver fibrosis 
in rats that were fed a choline- and L-amino acid-deficient diet 
or thioacetamide to induce fibrosis. Thus, inhibiting COX-2 
seems to prevent many different types of liver damage from a 
variety of causes in animals. In a recent report, Edfawy, et al.16 
suggested that the hepatoprotective effect of COX-2i could be 
ascribed to its antioxidant potential, free radical scavenging 
properties, anti-inflammatory effect, and ability to abrogate 
apoptosis via suppression of active caspase 3. In another study, 
selective COX-2i played a role in decreasing portal hyperten-
sion via its dual inhibitory effects on intrahepatic fibrosis and 
angiogenesis.17 The antifibrotic effects of COX-2i have been 
shown in models of fibrosis in other organs including the 
heart,25 lung,26 kidney,27,28 and peritoneum.29 To our knowledge, 
however, no study of human subjects has found that COX-2i 
can prevent liver damage; the present study is the first to find 
an ameliorating effect of COX-2i in humans with chronic liver 
disease.
In this study, the study group initially had a higher mean LSS, 
which indicates more advanced liver disease compared to the 
control group. This difference in patient groups might have 
been caused by the voluntary grouping of the patients. Sicker 
patients may want another option to manage their chronic liver 
disease. However, after medication with COX-2i, most patients 
in the study group had improved LSS. Although LSS decreased 
over time in both groups, it was significantly decreased only in 
the study group. Thus, treatment with COX-2i can reduce the 
LSS in patients with chronic liver disease after Kasai portoen-
terostomy for BA.
Meloxicam is a non-steroidal anti-inflammatory drug used 
to treat pain and inflammation caused by osteoarthritis or rheu-
matoid arthritis in adults and children who are at least 2 years 
old. The usual pediatric dosage for juvenile rheumatoid arthri-
tis is 0.125 mg/kg/day, which was the dosage in our high-dose 
group. The maximal dose for juvenile rheumatoid arthritis is 7.5 
mg/day. No dosage adjustment is needed in patients with mild 
to moderate hepatic or renal insufficiency.30 Reduction of the 
LSS was achieved in our study group using the universal dosage 
for juvenile rheumatoid arthritis or even 50% of that dose. No 
adverse reaction related to the COX-2i was found after the 
1-year study period. The LSS in the study group was significantly 
decreased only after administration for 1 year (not for 6 months) 
compared to the control group. Therefore, we cautiously suggest 
that long-term treatment for 1 year may be necessary to reduce 
the LSS without drug side effects in pediatric patients with 
chronic liver disease.
At the midpoint of the study, we excluded three patients from 
the study group because of their elevated LSS to prevent possi-
ble hepatic adverse effects of the study drug. Doing so may 
have provided a potential bias in analyzing the result by com-
paring the study and control groups. However, two of the three 
excluded patients had a lower LSS than the mean LSS of the 
study group. Therefore, the bias from the exclusion of these 
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three patients may not be significant.
The LSS is known to be affected by liver fibrosis, cholestasis 
(which is correlated with serum bilirubin), and necroinflam-
mation of the liver (which is represented by elevated liver en-
zymes, AST or ALT).31-36 In our study, treatment with a COX-2i 
improved the LSS in cholestatic patients with BA who had un-
dergone a Kasai portoenterostomy; however, cholestasis, as 
measured by total bilirubin, and necroinflammatory activity of 
the liver, as measured by ALT or AST, were not changed. There-
fore, the decrease in LSS indicates that the COX-2i ameliorated 
liver fibrosis.
In conclusion, COX-2i has a beneficial effect on hepatic fi-
brosis in children with chronic liver disease after Kasai porto-
enterostomy for BA. Accordingly, COX-2i may have a preventive 
effect against hepatic fibrosis in our study group, considering the 
progression of hepatic fibrosis in the patients with BA even after 
Kasai portoenterostomy. COX2i may be a promising new treat-
ment for preventing or reducing hepatic fibrosis after Kasai 
portoenterostomy for BA. Long-term treatment with a univer-
sal dose of a COX-2i was safe and did not lead to complications 
in these young patients with chronic liver disease. Further stud-
ies are needed to determine the optimal duration and dosage 
of the COX-2i in children with chronic liver disease and the op-
timal time to begin therapy with a COX-2i after the initial Kasai 
procedure.
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